A new study published in The Lancet journal showed that patients with type 2 diabetes and symptomatic peripheral arterial ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first ...

Maximum walking distance at 52 weeks was significantly improved with semaglutide. 2. There were fewer treatment-related ...

Patients (67 years old on average, about 25% women, 67% white) were randomized to receive semaglutide (1 mg) or placebo for one year (52 weeks). Researchers assessed maximal walking distance - the ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

And the mean improvement in walking distance in the semaglutide group was approximately 40 meters," Bonaca reported. An improvement of 20 meters on a flat surface would be considered clinically ...

Perspective from Eugenia Gianos, MD CHICAGO — Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, according to data from the ...

The researchers found that the estimated median ratio to baseline in maximum walking distance at week 52 was significantly greater in the semaglutide group versus the placebo group (1.21 versus 1. ...

“The significant improvements in walking distance and patient-reported quality of life observed with semaglutide 1.0 mg in the STRIDE trial are promising and represent an important step forward ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...